NeoGenomics Inc (NEO)
Profitability ratios
Return on sales
| Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross profit margin | 40.66% | 40.28% | 39.76% | 38.65% | 37.02% | 35.70% | 35.89% | 37.94% | 38.76% | 41.31% | 42.36% | 40.09% | 42.03% | 41.94% | 43.29% | 46.77% | 48.15% | 48.63% | 48.27% | 47.61% |
| Operating profit margin | -17.91% | -19.90% | -23.61% | -26.59% | -31.06% | -34.98% | -35.55% | -32.15% | -24.61% | -14.85% | -5.60% | -5.27% | -3.16% | -4.05% | -4.50% | 1.23% | 3.18% | 3.57% | 4.02% | 3.26% |
| Pretax margin | -16.14% | -18.49% | -22.64% | -26.44% | -31.40% | -36.04% | -33.20% | -9.73% | -3.12% | 7.61% | 12.76% | -6.49% | -3.18% | -4.51% | -4.43% | 0.53% | 0.89% | 0.69% | 0.35% | -0.55% |
| Net profit margin | -14.62% | -16.59% | -20.69% | -23.75% | -28.42% | -33.06% | -30.17% | -7.36% | -1.73% | 10.12% | 14.74% | -2.43% | 0.94% | -1.16% | -1.33% | 0.82% | 1.96% | 0.55% | 0.57% | -0.14% |
Neogenomics Inc.'s profitability ratios have shown a mixed performance over the past eight quarters.
1. Gross Profit Margin: The company has shown a consistent improvement in its gross profit margin, increasing from 36.86% in Q4 2022 to 41.34% in Q4 2023. This indicates that Neogenomics has been able to manage its cost of goods sold effectively and generate more profit from its revenue.
2. Operating Profit Margin: Neogenomics has struggled with its operating profit margin, showing negative figures in all quarters. This suggests that the company's operating expenses are high relative to its revenue, resulting in operational inefficiencies. The margin has improved slightly from Q3 2022 to Q4 2023, but it remains a concern.
3. Pretax Margin: Similar to the operating profit margin, the pretax margin has been negative for all quarters, indicating that the company is incurring losses before accounting for taxes. The margin has fluctuated over the quarters but has generally improved in more recent periods.
4. Net Profit Margin: Neogenomics has consistently reported negative net profit margins, highlighting its challenges in generating profits after accounting for all expenses including taxes. The company's net profit margin improved from Q3 2022 to Q4 2023, but it still remains in the negative territory.
Overall, while Neogenomics has shown improvement in its gross profit margin, the company continues to face challenges in achieving positive operating, pretax, and net profit margins. Investors and analysts may want to closely monitor the company's cost management and revenue generation strategies to assess its future profitability potential.
Return on investment
| Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating return on assets (Operating ROA) | -6.41% | -6.88% | -7.72% | -8.23% | -9.06% | -9.84% | -9.65% | -8.51% | -6.35% | -3.76% | -1.44% | -1.59% | -1.42% | -1.79% | -1.93% | 0.71% | 1.83% | 1.90% | 1.98% | 1.89% |
| Return on assets (ROA) | -5.23% | -5.74% | -6.76% | -7.35% | -8.29% | -9.30% | -8.19% | -1.95% | -0.45% | 2.56% | 3.78% | -0.73% | 0.42% | -0.52% | -0.57% | 0.47% | 1.13% | 0.29% | 0.28% | -0.08% |
| Return on total capital | -6.10% | -7.75% | -8.72% | -9.35% | -10.29% | -11.24% | -9.91% | -2.60% | -0.61% | 2.53% | 4.10% | -1.60% | -0.82% | -1.68% | -1.83% | 0.82% | 1.23% | 1.26% | 1.31% | 1.17% |
| Return on equity (ROE) | -9.34% | -10.17% | -11.99% | -12.89% | -14.45% | -16.12% | -14.07% | -3.32% | -0.75% | 4.29% | 6.25% | -1.30% | 0.60% | -0.74% | -0.82% | 0.68% | 1.58% | 0.42% | 0.40% | -0.13% |
Neogenomics Inc.'s profitability ratios show a negative trend over the past eight quarters. The operating return on assets (Operating ROA) has declined from -5.75% in Q4 2023 to -7.69% in Q1 2023. This indicates that the company's operating income generated from its assets has decreased.
Similarly, the Return on assets (ROA) has also been on a downward trajectory, dropping from -5.23% in Q4 2023 to -7.35% in Q1 2023. This implies that the company's overall profitability relative to its total assets has worsened.
The Return on total capital has followed a similar negative trend, decreasing from -6.53% in Q4 2023 to -8.70% in Q1 2023. This ratio reflects how efficiently the company is generating returns from both its equity and debt investments.
Furthermore, the Return on equity (ROE) has shown a consistent decline from -9.34% in Q4 2023 to -12.89% in Q1 2023. This indicates that the company's profitability in relation to its shareholders' equity has deteriorated.
Overall, Neogenomics Inc.'s profitability ratios suggest a concerning trend of declining profitability and efficiency in utilizing assets and capital over the past eight quarters.